

In-Depth Analysis Of The Global Familial Amyloid Polyneuropathy FAP market: Key Drivers And Forecast 2025-2034

*The Business Research Company's
Familial Amyloid Polyneuropathy FAP
Global Market Report 2025 – Market Size,
Trends, And Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, July 3, 2025

/EINPresswire.com/ -- The [Familial
Amyloid Polyneuropathy FAP market](#)

[size](#) has witnessed steady growth, going from \$1.52 billion in 2024 to an estimated \$1.65 billion in 2025. This growth translates into a compound annual growth rate CAGR of 8.4%. What's driving this growth? Increasing prevalence of FAP, rising awareness and improved genetic testing, adoption of novel therapeutic options, targeted treatments, and a significant investment in

“

Save 30% on all global
market reports with code
ONLINE30 – stay informed
on tariff changes,
macroeconomic trends, and
more”

*The Business Research
Company*

amyloidosis therapies research. Additionally, the growing geriatric population, which is more susceptible to amyloid-related neuropathies, continues to fuel the growth in this sector.

What Does The Future Look Like For The [FAP Market](#)?

Over the next decade, the FAP market is predicted to continue its upward trajectory, reaching \$2.25 billion by 2029. This growth - a projected CAGR of 8.1% - will likely be spurred by several factors. These include governmental initiatives and funding for rare disease treatments,

increasing clinical trials evaluating innovative treatment options, rising patient advocacy groups driving demand for superior therapies, expanding access to healthcare infrastructure in emerging markets, and the advent of advanced diagnostic tools. Major trends for this period include advancements in genetic sequencing technologies, integrated personalized medicine, improved technologies in biomarker identification, advancements in drug delivery systems, and the integration of digital health tools and telemedicine.

Get Your Free Sample Market Report:



What Are The Key Drivers Propelling The Growth Of The FAP Market?

To further the growth of FAP market, gene therapy is expected to play a significant role. Gene therapy modifies or replaces defective genes, addressing the root cause of diseases. It targets and fixes damaged genes offering permanent cures beyond mere symptom relief. Specifically for FAP, gene therapy concentrates on correcting or suppressing the faulty transthyretin TTR gene, preventing the formation of harmful amyloid proteins which reduces amyloid deposits, slowing disease progression and preserving nerve function. Various studies including one by the American Society of Gene & Cell Therapy ASGCT and Cyteline - noted an increase in Phase II gene therapies, further propelling the growth of the FAP market.

What Key Player Strategies Are Driving The FAP Market?

Prominent industry players in the FAP market include Pfizer Inc., AstraZeneca plc, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., NYU Langone Hospitals, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Mount Sinai Medical Center, PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Mayo Foundation for Medical Education and Research, Arcturus Therapeutics Inc., Prothena Corporation plc, Precision BioSciences Inc., Intellia Therapeutics Inc., Creative Biolabs, Stanford Health Care, Attralus Inc., Duke University Health System, YolTech Therapeutics.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/familial-amyloid-polyneuropathy-global-market-report>

What Are The Emerging Trends In The FAP Market?

Many of these FAP market industry leaders are continually innovating to develop advanced treatment options such as RNA interference RNAi therapeutics. Using this treatment, disease-causing genes are targeted at their messenger RNA mRNA, blocking harmful protein production and tackling genetic diseases at their source. One example of this is AMVUTTRA vutrisiran, a drug by Alnylam Pharmaceuticals, which has received FDA approval for treating cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis ATTR-CM. By lowering the production of TTR protein, this drug significantly reduces cardiovascular mortality, hospitalizations, and urgent heart failure visits.

How Is The FAP Market Segmented?

The FAP market report offers a detailed analysis segmented across several dimensions, including treatment, diagnosis, patient age group, distribution channel, and end-user. Major treatment subsegments include medication, gene therapy, supportive care, pain management, and symptomatic treatment. Patient age grouping involves pediatric, adult, and geriatric categories. Distribution channels include hospital pharmacies, retail pharmacies, online and specialty pharmacies, and direct sales. The end-user segment comprises hospitals, specialty clinics, research institutes, among others.

What Are The Regional Insights In The FAP Market?

Among the regions analyzed, North America was the largest player in the FAP market as of 2024. However, Asia-Pacific is forecasted to be the fastest-growing region, offering numerous opportunities for market players.

Browse Through More Similar Reports By The Business Research Company:

Peripheral Neuropathy Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report>

Transthyretin Amyloidosis Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report>

Diabetic Neuropathy Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report>

[About The Business Research Company](#)

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)
[Facebook](#)
[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/827676546>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.